Ipsen has go/no-go de­ci­sion to make af­ter biotech part­ner's Parkin­son's drug flunks PhI­Ib

Swedish biotech IR­LAB’s drug may have failed the pri­ma­ry end­point in a Phase IIb study in­volv­ing Parkin­son’s pa­tients, but ex­ecs still be­lieve they have a po­ten­tial treat­ment on their hands.

The com­pa­ny was test­ing mes­dopetam among pa­tients with lev­odopa-in­duced dysk­i­ne­sias, or se­vere in­vol­un­tary move­ments.

Ipsen paid $28 mil­lion up­front in 2021 to li­cense this drug, an oral dopamine D3-re­cep­tor an­tag­o­nist. The French phar­ma says it needs to ful­ly eval­u­ate the da­ta be­fore mak­ing a de­ci­sion about the fu­ture of its part­ner­ship with IR­LAB.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER